<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950012</url>
  </required_header>
  <id_info>
    <org_study_id>16OBHB</org_study_id>
    <nct_id>NCT02950012</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIO-CAT Microbials, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BIO-CAT Microbials, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of OPTI-BIOME™ (Bacillus subtilis
      MB40), a probiotic supplement, on bloating, gas and abdominal discomfort symptoms in
      otherwise healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly mean of the daily bloating scores</measure>
    <time_frame>4 weeks</time_frame>
    <description>Discomfort, Gas and Bloating questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly mean of the daily gas score (flatulence)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Discomfort, Gas and Bloating questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean of the abdominal pain score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Discomfort, Gas and Bloating questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Gastrointestinal Symptom Rating Scale (GSRS) score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean stool consistency scores</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bristol stool scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean number of bowel movements</measure>
    <time_frame>4 weeks</time_frame>
    <description>Daily Bowel Habits Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Rand SF-36</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal vital signs</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal complete blood panel</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal electrolytes</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal kidney function panel</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal liver function panel</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bloating</condition>
  <arm_group>
    <arm_group_label>OPTI-BIOME™ Bacillus subtilis MB40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OPTI-BIOME™ Bacillus subtilis MB40</intervention_name>
    <arm_group_label>OPTI-BIOME™ Bacillus subtilis MB40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18-75 years (inclusive) of age

          2. BMI 18.5-29.9 ±1 kg/m2

          3. Abdominal bloating intensity score ≥5 and at least two days of bloating over the 2
             weeks prior to screening (assessed at screening by Abdominal Bloating questionnaire)

          4. Participants categorized as 'high bloaters' as defined by an average bloating score ≥
             5 during the run-in period assessed at baseline by question 3 of the Modified Daily
             Abdominal Discomfort, Gas, and Bloating Questionnaire, AND/OR, participants
             categorized as 'high frequency bloaters' as defined by greater than 7 days of high
             bloating (defined above) during the run-in period.

               -  For females, this should not include abdominal discomfort or bloating experienced
                  during menstruation, if such symptoms occur due to menstrual cycle females should
                  go through another run-in period.

          5. If female, participant is not of child bearing potential, which is defined as females
             who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are
             post-menopausal (natural or surgically with &gt; 1 year since last menstruation) OR

             Females of childbearing potential must agree to use a medically approved method of
             birth control and have a negative urine pregnancy test result. Acceptable methods of
             birth control include:

               -  Hormonal contraceptives (stable for 1 month) including oral contraceptives,
                  hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing),
                  injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant
                  System)

               -  Double-barrier method

               -  Intrauterine devices

               -  Non-heterosexual lifestyle or agrees to use contraception if planning on changing
                  to heterosexual partner(s)

               -  Vasectomy of partner (shown successful as per appropriate follow-up)

          6. Healthy as determined by laboratory results, medical history, and physical exam

          7. Agrees to abstain from consuming unpasteurized bacteria-fermented foods including
             cheese and yogurt for 1 week prior to screening visit and throughout the study

          8. Agrees to abstain from using fiber supplements 2 weeks prior to screening and for the
             duration of the study

          9. Agrees to maintain current dietary habits and activity/training levels for two weeks
             prior to baseline and for the course of the study

         10. Agrees to avoid probiotics for one week prior to screening and for the course of the
             study

         11. Willingness to complete all the study requirements and attend all clinic visits.

         12. Has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          1. Females who are pregnant, breastfeeding, or planning to become pregnant during the
             course of the trial

          2. History of chronic inflammation or structural abnormality of the digestive tract
             (inflammatory bowel disease, duodenal or gastric ulcer, intestinal obstruction, or
             symptomatic cholelithiasis)

          3. Nocturnal and/or progressive abdominal pain (abdominal pain that increases in
             intensity and is consistent on regular basis)

          4. Significant weight loss over the past 3 months (significance to be determined by the
             Qualified Investigator)

          5. Type 1 and type 2 diabetes

          6. History of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis,
             gastric retention or obstruction, bowel resection, rectocele, or colostomy

          7. Cancer except skin cancers completed excised with no chemotherapy or radiation
             following and with a negative follow up.

          8. Diagnosis of adenomatous polyposis, irritable bowel syndrome, chronic gastritis or
             functional dyspepsia, crohn disease, and celiac disease Renal or hepatic insufficiency

          9. Gastrointestinal bleeding or acute infection

         10. Immunodeficiency

         11. History of organ transplant

         12. Use of antibiotics within 4 weeks of randomization Routine (at least 3 times per week)
             consumption of probiotic or prebiotic supplements or supplemented foods and are
             unwilling to stop at least one week prior to screening and throughout the study

         13. Use of immunosuppressant drugs

         14. Change in anti-psychotic medication within 3 months of randomization

         15. Abdominal surgery within 6 months of randomization

         16. Plan to donate blood during the study or within 30 days of completing the study

         17. Participation in a clinical research trial within 30 days prior to randomization

         18. Allergy or sensitivity to study supplement or placebo ingredients

         19. Alcohol abuse (&gt;2 standard alcoholic drinks per day) or drug abuse within the last 6
             months

         20. Use of Medicinal Marijuana

         21. Cognitively impaired and/or unable to give informed consent

         22. Unstable medical conditions

         23. Clinically significant abnormal laboratory results at screening

         24. Any other condition which in the Qualified Investigator's opinion may adversely affect
             the volunteer's ability to complete the study or its measures or which may pose
             significant risk to the volunteer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD`</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mal Evans, PhD</last_name>
    <phone>(519) 438-9374</phone>
    <phone_ext>239</phone_ext>
    <email>mevans@kgksynergize.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KGK Clinical Trials Center</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <zip>92610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gia Radoias</last_name>
      <phone>949-464-4451</phone>
      <email>gradoias@kgkscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KGK Clinical Trials Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Wills, NP</last_name>
      <phone>407-674-7311</phone>
      <email>dwills@kgkscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mal Evans, PhD</last_name>
      <phone>(519) 438-9374</phone>
      <phone_ext>239</phone_ext>
      <email>mevans@kgksynergize.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>BIO-CAT Microbials, LLC</investigator_affiliation>
    <investigator_full_name>Dr. Tetyana Pelipyagina</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Bloating</keyword>
  <keyword>Abdominal Discomfort</keyword>
  <keyword>Gas</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Bacillus Subtillis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

